---
title: IgG Subclass Switch in Volunteers Repeatedly Immunized with the Full-Length
  <em>Plasmodium falciparum</em> Merozoite Surface Protein 1 (MSP1)
date: '2024-02-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38400191/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240225170529&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Vaccines are highly effective tools against infectious diseases and are
  also considered necessary in the fight against malaria. Vaccine-induced immunity
  is frequently mediated by antibodies. We have recently conducted a first-in-human
  clinical trial featuring SumayaVac-1, a malaria vaccine based on the recombinant,
  full-length merozoite surface protein 1 (MSP1(FL)) formulated with GLA-SE as an
  adjuvant. Vaccination with MSP1(FL) was safe and elicited sustainable IgG antibody
  titers that ...
disable_comments: true
---
Vaccines are highly effective tools against infectious diseases and are also considered necessary in the fight against malaria. Vaccine-induced immunity is frequently mediated by antibodies. We have recently conducted a first-in-human clinical trial featuring SumayaVac-1, a malaria vaccine based on the recombinant, full-length merozoite surface protein 1 (MSP1(FL)) formulated with GLA-SE as an adjuvant. Vaccination with MSP1(FL) was safe and elicited sustainable IgG antibody titers that ...